(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 June 2003 (12.06.2003)

PCT

(10) International Publication Number
WO 2003/047420 A3

(51) International Patent Classification[7]: A61K 38/00, G01N 33/53, 33/537, C12N 15/00, 5/00

(21) International Application Number:
PCT/US2002/038555

(22) International Filing Date: 2 December 2002 (02.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/338,100	30 November 2001 (30.11.2001)	US
60/337,961	30 November 2001 (30.11.2001)	US
10/245,850	16 September 2002 (16.09.2002)	US
02256808.3	30 September 2002 (30.09.2002)	EP

(71) Applicant *(for all designated States except US)*: **CHEMOCENTRYX INC.** [US/US]; 1539 Industrial Road, San Carlos, CA 94070 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BURNS, Jennifer, M.** [US/US]; 24 Poinsettia Avenue, San Mateo, CA 94403 (US). **MIAO, Zhenhua** [CN/US]; 7070 Rainbow Drive, #2, San Jose, CA 95129 (US). **WEI, Zheng** [US/US]; 75 Duane Street, Apt. 12, Redwood City, CA 94062 (US). **HOWARD, Maureen, C.** [AU/US]; 12700 Viscaino Road, Los Altos, CA 94022 (US). **PREMACK, Brett, A.** [CA/US]; 409 Portofino Drive, #2, San Carlos, CA 94070 (US). **SCHALL, Thomas, J.** [US/US]; 530 Webster Place, #5, Palo Alto, CA 94301 (US).

(74) Agents: **HINSCH, Matthew, E.** et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, Eighth Floor, San Francisco, CA 94111 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*

(88) Date of publication of the international search report:
26 February 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS

(57) Abstract: Compositions and Methods for Detecting and Treating Diseases and Conditions Related to Chemokine ReceptorsABSTRACT OF THE DISCLOSUREThe present invention provides methods for identifying an agent that specifically binds and/or modulates one topology of chemokine receptor but not a second topology of the receptor. Such agents are useful as therapeutics for diseases or conditions associated with a particular chemokine receptor topology. Moreover, the agents are useful for detecting a particular topology of a chemokine receptor, thereby diagnosing disease or predisposition for a disease. In addition, the agents are useful for identifying and isolating cells that express a particular topology of a chemokine receptor.

WO 2003/047420 A3